Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intermolecular Inc    IMI

INTERMOLECULAR INC

(IMI)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

WeissLaw LLP : Investigates Intermolecular, Inc. Acquisition

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2019 | 09:02pm EDT

NEW YORK, May 15, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Intermolecular, Inc. ("Intermolecular" or the "Company") (NASDAQ: IMI) in connection with the proposed acquisition of the Company by a wholly owned subsidiary of Merck KGaA.  Under the terms of the acquisition agreement valued at $62 million, shareholders will receive $1.20 per share in cash. 

WeissLaw LLP (PRNewsfoto/WeissLaw LLP)

If you own IMI shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, please contact:

Joshua Rubin
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Visit our website
http://www.weisslawllp.com/

Or follow us on Twitter @MarketsAlert

WeissLaw is investigating whether Intermolecular's Board acted to maximize shareholder value prior to entering into the agreement. 

WeissLaw is concentrating its investigation on whether Intermolecular's Board conducted a fair process in agreeing to the proposed acquisition, and whether the proposed acquisition undervalues the Company. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com.

 

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/weisslaw-llp-investigates-intermolecular-inc-acquisition-300851308.html

SOURCE WeissLaw LLP


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INTERMOLECULAR INC
08/08INTERMOLECULAR : 2Q Earnings Snapshot
AQ
08/08INTERMOLECULAR : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
08/08INTERMOLECULAR INC : Results of Operations and Financial Condition, Financial St..
AQ
08/08INTERMOLECULAR : Reports Second Quarter 2019 Financial Results
PR
08/01INTERMOLECULAR TO LEAD SESSION ON 3D : Current Implementations and Future Trends..
PR
07/18Intermolecular Stockholders Agree to Merck KGaA Acquisition
DJ
07/17INTERMOLECULAR INC : Submission of Matters to a Vote of Security Holders, Other ..
AQ
07/17INTERMOLECULAR : Stockholders Approve Merck KGaA, Darmstadt, Germany's Proposed ..
PR
07/02INTERMOLECULAR INVESTOR ALERT BY THE : Kahn Swick & Foti, LLC Investigates Adequ..
BU
06/01INTERMOLECULAR INVESTOR ALERT BY THE : Kahn Swick & Foti, LLC Investigates Adequ..
BU
More news